An infection that is caused by the Chikungunya virus, which is transmitted by mosquitoes; it is characterized by fever and severe arthralgia.
Comprehensive, easy-to-understand information about this condition
How we create this content →Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 3, 2026
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning chikungunya
Updated Feb 16, 2026
Researchers have developed a universal multiepitope vaccine against chikungunya virus using reverse vaccinology and immunoinformatics approaches. This innovative design could enhance vaccine efficacy and broaden protection against the virus.
VV261 shows promise as a potent antiviral candidate against Chikungunya virus, with preclinical studies indicating significant efficacy. The drug's pharmacokinetics suggest a maximum blood concentration of 2000 ng/mL, far exceeding the effective concentration needed for inhibition.
The CDC highlights areas at risk for chikungunya transmission, advising U.S. travelers to consider vaccination. This guidance reflects ongoing public health efforts to manage and prevent outbreaks.
CDC reports a significant rise in U.S. counties with Aedes aegypti and Aedes albopictus mosquitoes, which are capable of spreading chikungunya, dengue, and Zika viruses. This increase highlights the growing public health concern regarding these vector-borne diseases.
The chikungunya outbreak is escalating in the Caribbean, Central, and South America, with no signs of abating. While the U.S. experiences a decrease in mosquito populations, affected regions continue to face significant health risks.